Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis.

AUTOR(ES)

Swinson, D R

RESUMO

Dapsone given over 14 weeks in a dose of 50 mg a day for 1 week and thereafter 100 mg a day was found to have a beneficial effect in rheumatoid arthritis when compared with placebo administration to a matched group of patients. Significant improvement in 5 out of 7 clinical measurements and in erythrocyte sedimentation rate, viscosity, C-reactive protein was found in those patients taking dapsone. There was significant improvement compared to the placebo group in 2 out of the 7 clinical measurements and again in all 3 acute-phase reactants. The drug was quite well tolerated over the 14-week duration of the trial. The tendency to cause haemolysis will be its main limiting factor as a practical alternative to other suppressive agents currently in use.

Documentos Relacionados

• Azathioprine: a controlled, double-blind trial in rheumatoid arthritis.
• Proceedings: A double-blind comparative trial of cyclophosphamide and gold in rheumatoid arthritis.
• A double-blind controlled trial of etretinate (Tigason) and ibuprofen in psoriatic arthritis.
• Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.
• No effect of transfer factor in juvenile rheumatoid arthritis by double-blind trial.